Search results
The antiviral remdesivir should not be used as treatment for hospitalized Covid-19 patients, the World Health Organization said Thursday, only a month after the Food and Drug Administration ...
At best, one large, well-designed study found remdesivir modestly reduced the time to recover from COVID-19 in hospitalized patients with severe illness. A few smaller studies found no impact of treatment on the disease whatsoever.
No studies have found that remdesivir was responsible for killing COVID-19 patients. Medical experts explained that remdesivir is given to patients who are at the highest risk of death...
This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
The 28-day mortality rate was 0.5 per person-month in the remdesivir group and 0.6 per person-month in the control group. Remdesivir treatment was associated with a statistically significant 17% reduction in inpatient mortality among patients hospitalized with COVID-19 compared with propensity score–matched control patients (hazard ratio, 0. ...
Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).
But a retired chiropractor misleadingly claims on a viral clip on social media that the drug is “killing people.” Studies have shown that remdesivir can lead to faster recovery times for ...
